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Cervical cytology reported as negative and risk of adenocarcinoma of the
cervix: no strong evidence of benefit
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Summary The relationship between negative cervical cytology reports and risk of adenocarcinoma of the
cervix was evaluated in a case-control study of 113 cases and 452 controls. All cases and controls had
received at least two negative cytology reports. There was no significant difference between the cases and
controls in the number of negative cytology reports or in history of cervical abnormality; while a test for trend
in the time since last negative cytology report was significant (P<0.001), the estimated benefit was very
modest. Although the estimates of relative protection were higher in women aged less than 35 years than in
women aged 35-69 years, this difference was not statistically significant. These results suggest that cervical
screening as practised in the 1970s and 1980s was much less effective in preventing adenocarcinoma than
squamous carcinoma of the cervix.
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The incidence of adenocarcinoma of the cervix among
women aged less than 35 years more than doubled between
the late 1960s/early 1970s and the early 1980s (Peters et al.,
1986; Schwartz and Weiss, 1986; Chilvers et al., 1987). The
reasons for this increase are poorly understood. While one
case series has documented a higher prevalence of oral
contraceptive use among women with adenocarcinoma
(Dallengach-Hellweg, 1984), other studies have found no
evidence of different oral contraceptive use between women
with adenocarcinoma and women with squamous malignancy
(Silcocks et al., 1987) on between women with adenocar-
cinoma and control women (Brinton et al., 1987; Parazzini et
al., 1988).
Case-control studies have become an established method
of evaluating screening programmes. The degree to which
adenocarcinoma of the cervix can be prevented by cervical
cytology screening has not been well defined. While some
published case-control studies have included adenocar-
cinoma cases in their series (Clarke and Anderson, 1979; La
Vecchia et al., 1984; Brinton et al., 1987; Olesen, 1988;
Celentano et al., 1989; Shy et al., 1989; Cohen, 1993), the
cases have been few in number, constituting only a small
minority of all cases. One study of40 patients with adenocar-
cinomai found no significant difference in self-reported screen-
ing history between cases and controls (Brinton et al., 1987).
No validation of the screening history was undertaken, and it
appears that the time interval since the last negative
Papanicolaou smear report was not specifically sought. Three
studies have commented that Papanicolaou smear screening
appears to be less effective for the prevention of adenocar-
cinoma than for squamous carcinoma but have not provided
separate analyses for adenocarcinoma (Clarke and Anderson,
1979; Olesen, 1988; Shy et al., 1989).
We undertook a case-control study to evaluate the dura-
tion of low risk for adenocarcinoma of the cervix after
negative cervical cytology results. Cases were diagnosed
mainly in the 1980s when screening was well established in
Australia. Adenocarcinoma of the cervix constituted 13% of
all cervical malignancies at the time of the study (Giles et al.,
1992). Screening histories were compiled from the files of a
large central laboratory, Victorian Cytology Service. From
the commencement of screening in 1965 until the mid-1980s,
most smears of Victorian women were evaluated by this
laboratory which reports in excess of 250 000 Papanicolaou
smears per year.
Methods
Cases comprised all women aged less than 70 years who were
registered with the Victorian Cancer Registry as having
invasive adenocarcinoma of the cervix diagnosed between
1982 and 1992 and who had two or more negative cytology
reports preceding the diagnosis of cancer. 1982 was selected
as the commencement date for case accrual as this was the
first year of compulsory cancer registration in Victoria. At
the time of case selection, cancer registrations were complete
to the end of 1990.
Twelve patients with microinvasive adenocarcinoma with
two or more preceding negative cytology reports were ex-
cluded from the study as it is local policy to regard such
women as successes ofthe screening programme. By contrast,
patients with invasive disease are regarded as failures of the
screening programme. Patients with adenosquamous car-
cinoma of the cervix were also excluded from the study.
Four control women were randomly selected from com-
puterised laboratory files, matched to the year of birth of the
case. The exit date for cases and matched controls was
defined as 6 months before the date of histological diagnosis
of cancer in the case. To be eligible as controls, women were
required to have two or more negative cytology reports
before the exit date ofthe matched case, to be still resident in
Victoria and not to have had a hysterectomy by the exit date.
To fulfil these last two criteria, evidence ofcontinued cervical
screening during the 2 years before the exit date or at any
time after the exit date was needed. This information was
obtained either from laboratory records or from the Vic-
torian Cervical Cytology Registry, a centralised repository of
all screening tests since 1990.
The number of negative cytology reports issued for each
case and control was determined. A minimum of two
negative cytology reports was required for participation in
the study to reduce the probability of false-negative cytology
reports having been issued. Negative cytology was defined as
reports of no abnormal cells or reports of minor reactive or
inflammatory change. Atypia, low- or high-grade intra-
epithelial change or inconclusive reports were regarded as
positive cytology. Neither cases nor controls were excluded
because of a history of cytological abnormality. Subjects
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if they had positive cytology reported 2 or more years before
the exit date.
Conditional logistic regression was used to estimate
relative protection (the inverse of relative risk) by time since
last negative cytology, number of negative cytology reports
and history of abnormality. Separate analyses were under-
taken for young women (<35 years) and older women (35 +
years). The median time interval between negative cytology
reports was determined for cases and controls within each
age group.
Results
A total of 113 cases were eligible for the study, 44 (39%) of
whom were aged less than 35 years at the time of cancer
diagnosis. Thirteen cases (five young, eight older women) had
negative cytology within the 6 month period between the exit
date and the date of cancer diagnosis. These women still
remained eligible for the study on the basis of two or more
earlier negative smears. Eight cases and 19 controls had a
history of cervical abnormality.
Conditional logistic regression revealed that none of the
three variables (time since last negative smear, number of
negative smears or history of abnormality) was significantly
different between cases and controls (see Table I). The rela-
tionship with time since the last negative cytology report was
variable. When the last negative cytology report was within 2
years of the exit date, some degree of protection was evident
although it did not reach statistical significance. However,
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when the last negative cytology report was between 2 and 10
years before the exit date, there was no evidence of protec-
tion. A test for trend in increasing relative protection by time
since last negative smear was significant (P<0.001). How-
ever, the estimated relative protections were not greater than
1 except where the time period since last negative smear was-
less than 2 years. Further, the largest relative protection of
1.6 corresponds to a very modest benefit, particularly in
comparison with benefits for squamous cancer. The test for
trend in relative protection by number of negative smears
was not significant (P = 0.8).
There was no evidence of a modifying effect of age on the
risk of adenocarcinoma after negative cytology (test for effect
modification, P = 0.4). However, the pattern of relative pro-
tection estimates differed between the two age groups (see
Table II). Because of the small numbers of women involved,
the baseline for this analysis was taken as last negative
cytology report 6 or more years before the exit date. For
younger women, relative protection declined from 11.1 dur-
ing the first year and 7.8 during the second year to 3.8 when
the last negative cytology report was between 3 and 6 years
before the exit date. There was no clear relationship between
relative protection estimates and time since last negative
cytology report among older women.
The median time interval between negative cytology
reports was 1.9 years for younger cases compared with 2.0
years for their controls. Older women were screened mar-
ginally less frequently with the median time interval between
negative cytology reports being 2.1 years for both cases and
controls. Thus, while the median time between negative
smears was similar for cases and controls, the timing of the
smears in relation to the exit date differed.
Table I Relative protection against adenocarcinoma of the cervix in relation to timing and
number of negative cytology reports and past history of abnormality
Risk factor No. of cases No. of controls Relative protection' 95% CI
Time since last negative report (years)
10+ 6 24 1.0
5-9.9 19 49 0.6 0.2-1.8
3-4.9 33 68 0.5 0.2-1.4
2-2.9 13 54 0.9 0.3-3.1
1 -1.9 20 110 1.3 0.4-4.0
0-0.9 22 147 1.6 0.5-5.0
Number of negative reports
2 39 137 1.0
3 29 107 0.9 0.5-1.7
4 18 77 1.0 0.5-1.9
5 12 47 0.8 0.4-1.8
6 6 32 1.1 0.4-3.0
7+ 9 52 1.2 0.5-3.0
Past history of cervical abnormality
No 105 433 1.0
Yes 8 19 0.5 0.2-1.3
aAfter adjustment for the other variables.
Table II Relative protection against adenocarcinoma of the cervix in relation to timing of
negative cytology reports by age group
Time since last negative
report (years) No. of cases No. of controls Relative protection' 95% CI
<35
6+ 6 6 1.0
3-5.9 11 32 3.8 0.9-15
2-2.9 7 25 4.9 1.0-24
1 -1.9 10 50 7.8 1.8-34
0-0.9 10 63 11.1 2.4-52
35-69
6+ 14 47 1.0
3-5.9 27 56 0.5 0.2-1.2
2-2.9 6 29 1.1 0.4-3.5
1 -1.9 10 60 1.5 0.6-3.8
0-0.9 12 84 1.8 0.7-4.6
aAfter adjustment for the other variables.Adnocarcinoma risk
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Discussion
This large study found little difference in the screening his-
tories of women with adenocarcinoma of the cervix com-
pared with control women. This result confirms the findings
of Brinton's smaller study (1987). This is very different to
studies of women with squamous cancer of the cervix, which
have all found significant underscreening of women com-
pared with controls for at least 3 years before diagnosis of
cancer (Clarke and Anderson, 1979; La Vecchia et al., 1984;
MacGregor et al., 1985; Brinton et al., 1987; Olesen, 1988;
van der Graaf et al., 1988; Celentano et al., 1989; Klassen et
al., 1989; Shy et al., 1989; Cohen, 1993). A large meta-
analysis found underscreening for 6 years (IARC Working
Group, 1986). This meta-analysis involved 162 cases of
squamous cancer among women with two or more negative
cytology reports recruited from seven geographic areas over
periods ranging from 11 to 23 years. Our study of 113 cases
drawn from one geographic area over an 11 year period is
therefore of substantial size; it had 88% power to detect a
halving in the risk of cancer within 3 years of a negative
cytology report at the 0.05 significance interval.
Cases were selected from Cancer Registry and laboratory
files. This study did not involve any personal contact with
women, and this has meant that no bias has been introduced
as a result of only survivors or women in comparatively good
health being available for interview. Controls were selected
from laboratory records and therefore represent the same
population of screened women from which cases were drawn.
Entry to the study required evidence that the control women
were still at risk ofcervical cancer on or around the exit date.
Given the high hysterectomy rate among older women,
failure to do this would have produced artificially low screen-
ing rates among control women. Overall, 57% of the control
women in this study were screened within 2 years of the exit
date; in comparison, 50% of Australian women aged 20-69
years were screened during the 2 year period, 1988-89 (Aus-
tralian Health Ministers, 1991). Thus, the stringent
requirements for eligibility as a control in this study have
possibly overestimated the screening history of control
women, increasing the estimates of relative protection.
Because the screening histories of both cases and controls
were compiled from laboratory records, this study has
avoided recall and reporting bias. It has been shown
repeatedly that women overestimate their screening history
and are not able to distinguish reliably between having a
smear and receiving a negative smear result (Walter et al.,
1988; Sawyer et al., 1989; Boyce et al., 1990; Bowman et al.,
1991). This study has not been able to adjust for other risk
factors for adenocarcinoma of the cervix. However these are
poorly defined, with published literature comprising two
case-control studies (Brinton et al., 1987; Parazzini et al.,
1988). The only risk factor common to both studies was
being overweight, a variable which is unlikely to be
associated with screening.
While the estimates of relative protection differed between
the two age groups, the differences did not reach statistical
significance. The suggestion that screening may be beneficial
for up to 2 years in younger women but not in older women
could reflect easier sampling of glandular cells in younger
women whose transformation zone is located closer to the
cervical os. The laboratory has never had an age differential
in its policy of provision of sampling instruments (such as
cytobrushes) specifically designed to sample from the
endocervical canal. Since 1989 when such instruments were
routinely provided to all doctors, sufficient supplies have
been made available for each doctor to use them regardless
of the age of the woman.
This study is unable to evaluate completely the benefits of
screening as it focused on screened women who developed
invasive cancer. It is possible that some adenocarcinomas
were prevented by detection of precancerous abnormalities.
The possible benefit could be clarified by a case-control
study that compared the screening histories of all women
diagnosed with adenocarcinoma with a control group
selected from the community, with case and control selection
not requiring participation in screening as an eligibility
criterion.
Nevertheless, we believe that adenocarcinoma among
screened women is a problem ofconsiderable magnitude. We
were able to detect 113 cases of adenocarcinoma which had
occurred among screened women; a parallel study of
squamous cancer which we are conducting over the same
time period has been able to detect 220 cases (53 younger,
167 older women). This ratio of approximately two
squamous to one adenocarcinoma is very different to the
ratio of 20 squamous to one adenocarcinoma which occurred
before screening reduced the incidence of squamous cancer
(Rombaut et al., 1966; Anderson and Fraser, 1976; Hurt et
al., 1977).
On a more optimistic note, it is possible that better detec-
tion of precancerous glandular abnormalities will have occur-
red since 1989 when endocervical brushes were introduced
into routine use. Our case-control study primarily reflects
the quality of cervical screening before this time. Columnar
cells from the endocervix are now reported in 80% of smears
compared with only 50% before the introduction of endocer-
vical brushes (Mitchell and Medley, 1993). However, reports
of precancerous endocervical disease remain quite rare, cons-
tituting fewer than 1 in 5000 cytology reports (Victorian
Cervical Cytology Registry, 1993). Further studies in this
area are warranted, particularly given the increasing
incidence of adenocarcinoma in young women.
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